logo
Why women might feel less angry as they age, new study reveals

Why women might feel less angry as they age, new study reveals

CTV News07-07-2025
Many women know midlife can bring big emotional changes, but a new study suggests one change might actually be positive: women tend to feel and express less anger as they get older.
The research , published in Menopause , the journal of The Menopause Society, analyzed self-reported data from more than 500 women aged 35 to 55 who participated in the Study of Midlife Women's Health and Stress (SMWHS). This group was followed through different stages of menopause to understand how their experiences, including emotions like anger, changed over time.
The study found that most types of anger decrease with age, especially as women move through menopause.
'Anger expression indicators decreased with age, suggesting emotion regulation may occur during midlife,' the researchers said.
The study looked at:
State anger: The kind of anger you feel in the moment
The kind of anger you feel in the moment Trait anger: To be anger-prone and experience difficulty letting go of it
To be anger-prone and experience difficulty letting go of it Anger temperament: A tendency to experience and express anger indiscriminately
A tendency to experience and express anger indiscriminately Anger reaction: Anger that flares up when you're criticized or treated unfairly
Anger that flares up when you're criticized or treated unfairly Anger expressed aggressively (anger-out): When you take your anger out on others
When you take your anger out on others Anger suppressed (anger-in): When you hold it in and keep it to yourself
When you hold it in and keep it to yourself Anger control: Ability to calm yourself down and manage your emotions
Ability to calm yourself down and manage your emotions Hostility: Antagonism toward someone or something, or constantly being ready for a fight
What did they find?
The study showed that many of these anger types, like anger reaction and hostility, drop significantly with age. Women were less likely to lash out, feel easily provoked, or hold a combative mindset as they got older.
Only anger that was kept in (anger-in) didn't seem to change with age. On the flip side, anger control actually improved, meaning women became better at handling difficult feelings.
The findings suggest that as women get older, they experience more complex emotions and develop better ways to regulate anger.
'Some of these changes may be seen in midlife and contribute to a sense of integration and maturity, supporting the development of generativity with aging,' the study said.
Why it matters
Researchers say anger in women hasn't been studied enough, especially during menopause.
'Despite evidence first published in 1980 linking dimensions of women's anger to coronary artery disease, a leading cause of death for women, the study of anger in midlife women has been limited,' they wrote, adding that it likely reflects 'the practice of discouraging women's expression of anger.'
The researchers say more studies are needed to understand how women deal with anger day-to-day, and how that knowledge could support mental health and well-being.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump administration to burn $13M worth of female contraceptives, despite NGO's offer to take them
Trump administration to burn $13M worth of female contraceptives, despite NGO's offer to take them

CBC

time9 minutes ago

  • CBC

Trump administration to burn $13M worth of female contraceptives, despite NGO's offer to take them

The U.S. State Department plans to incinerate roughly $13.2 million worth of women's contraceptives despite offers from multiple aid agencies to distribute the supplies at no cost. The supplies, which include various forms of birth control, were intended for family planning programs in low-income African nations. Instead, they've been sitting in a warehouse in Belgium for months after President Donald Trump's administration froze most foreign aid in January. MSI Reproductive Choices, a U.K.-based global reproductive health organization, says it offered to take the supplies and distribute them to those in need at no cost to the government, but their offer was rebuked. "To me that sends a really clear signal that this is an ideological position," Sarah Shaw, MSI's director of advocacy, told As It Happens guest host Paul Hunter. "This is just another front on the war on women that we're currently seeing coming out of the U.S., both domestically and internationally." Shaw says MSI was told through an intermediary that the government wants to sell the products at market value, which the charity could not afford to do. The United Nations' sexual and reproductive health agency, UNFPA, offered to buy the contraceptives outright, also to no avail, according to Reuters. The U.S. State Department did not respond to questions from CBC. But spokesperson Tommy Pigott told reporters on Thursday the government is "still in the process of determining the pathway forward." Belgium calls it a 'regrettable outcome' The supplies, valued at $9.7 million US, once belonged to the United States Agency for International Development (USAID), which the Trump administration has shut down. During a press briefing on Thursday, Pigott said the supplies do not include condoms or HIV medication, but rather "select products" purchased under the previous administration that "could potentially be abortifacients," meaning products that induce abortion. But aid agencies and media organizations say the supplies slated for destruction are designed to prevent unwanted pregnancies, not terminate them. Reuters, citing seven confidential sources close to the story, reports the warehouse contains contraceptive pills and implants, as well as intrauterine devices, all of which are forms of birth control. Pigott said the products could be in contravention of the Kemp-Kasten amendment, which prevents the government from supporting programs that engage in "coercive abortion or involuntary sterilization," as well as the Mexico City policy, a pact that prohibits the U.S. government from contributing to or working with organizations that provide abortion-related services or information. The latter could explain why the U.S. declined MSI's offer, says Shaw. Her organization refuses to comply with the Mexico City policy, which she and other aid organizations refer to as "the global gag order." But it doesn't explain why they've rejected similar overtures from others trying to prevent the contraceptives from going to waste at taxpayer expense, she said. The Belgian foreign ministry said Brussels had held talks with U.S. authorities and "explored all possible options to prevent the destruction, including temporary relocation." "Despite these efforts, and with full respect for our partners, no viable alternative could be secured. Nevertheless, Belgium continues to actively seek solutions to avoid this regrettable outcome," it said in a statement. "Sexual and reproductive health must not be subject to ideological constraints." Uproar in France The State Department previously confirmed it will spend $167,000 US ($228,000 Cdn) to incinerate the contraceptives at a facility in France that handles medical waste. That news is not sitting well in France, where lawmakers, reproductive health organizations and feminist groups are calling on the government to call it off. "We are following this situation closely and we support the will of the Belgian authorities to find a solution to avoid the destruction of contraceptives," France's foreign ministry said in a statement published by the Guardian. "The defence of sexual health and reproductive rights is a foreign policy priority for France." WATCH | Global health funding in a state of crisis: U.S. foreign aid cuts fuelling 'era of global health austerity': study 15 days ago After the White House's push to dismantle the United States Agency for International Development (USAID) cancelled billions of dollars in spending for foreign aid, researchers say global health funding is expected to reach a 15-year low. Read more: Shaw says she's grateful to the people in France who are championing this cause. "Even if we can't stop the destruction we're not going to let this go quietly," she said. "If this happens on French soil under a government that has a feminist foreign policy, I think that would be a great shame, a great shame." Doctors Without Borders calls plan 'reckless and harmful' Avril Benoît, the CEO of Doctors Without Borders in the U.S., called the plan a "reckless and harmful act against women and girls everywhere." "Contraceptives are essential and lifesaving health products," she said in a press release. "[Our organization] has seen first-hand the positive health benefits when women and girls can freely make their own health decisions by choosing to prevent or delay pregnancy — and the dangerous consequences when they cannot." Shaw agrees. She says the U.S. has made a big deal about finding government efficiencies as it slashes global aid and its own civil service. But every dollar spent on reproductive health, she says, leads to much greater savings down the road. "It makes no sense to me. If they really want efficiency, investing in family planning is the best investment you can make for development," she said. "You keep girls in schools. You break generational cycles of poverty. You create opportunity for a new generation of young women.

Hemophilia Pipeline Outlook Report 2025: Key 80+ Companies and Breakthrough Therapies Shaping the Future Landscape
Hemophilia Pipeline Outlook Report 2025: Key 80+ Companies and Breakthrough Therapies Shaping the Future Landscape

Globe and Mail

time2 hours ago

  • Globe and Mail

Hemophilia Pipeline Outlook Report 2025: Key 80+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's, 'Hemophilia Pipeline Insight, 2025,' report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Hemophilia Pipeline Outlook Report Key Takeaways from the Hemophilia Pipeline Report In July 2025, Novo Nordisk A/S announced a study is looking at how safe it is to switch from emicizumab to Mim8, in people with haemophilia A. Mim8 is a new medicine that is used to prevent bleeding episodes in people with haemophilia A. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected under the skin using a pen-injector either once every week, once every two weeks or once every month. The participants will be trained in using the pen injector. In July 2025, Pfizer announced a study to establish baseline prospective efficacy data of current FIX prophylaxis replacement therapy in the usual care setting of hemophilia B subjects, who are negative for nAb to AAV-Spark100, prior to the Phase 3 gene therapy study. In July 2025, Regeneron Pharmaceuticals announced a study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an experimental gene insertion therapy (the adding of a gene into your DNA) called REGV131-LNP1265, also called the "study drug". Gene insertion therapy aims to teach the body how to produce clotting factor long-term, without the need for factor replacement therapy. DelveInsight's Hemophilia pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Hemophilia treatment. The leading Hemophilia Companies such as Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others. Promising Hemophilia Pipeline Therapies such as NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601 for Injection, Fitusiran, Marstacimab, Fitusiran, BPA prophylaxis, Concizumab, PF-06741086 and others. Discover how the Hemophilia treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Hemophilia Clinical Trials and Studies Hemophilia Emerging Drugs Profile SerpinPC: Centessa Pharmaceuticals SerpinPC, a specific inhibitor of activated protein C (APC), for the treatment of hemophilia A and hemophilia B. SerpinPC has been observed to be well-tolerated in the clinical setting, associated with promising reductions in bleeding rates, and has PK suitable for infrequent subcutaneous dosing without the need for factor replacement. SerpinPC has human genetic target validation and established proof of concept Phase 2a clinical data. Fitusiran: Alnylam Pharmaceuticals Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in development for the treatment of hemophilia and rare bleeding disorders (RBDs) by their collaborators at Sanofi Genzyme. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Hemophilia. ASC 618: ASC Therapeutics ASC618 is an AAV8-based gene therapy for the treatment of hemophilia A, affecting approximately 1 of every 5000 live-born males. ASC618 incorporates a novel liver-specific promoter and a bioengineered, codon-optimized B domain-deleted FVIII variant; in preclinical studies, ASC618 exhibits at least a 10-fold increase in the biosynthesis and secretion of FVIII compared with native human FVIII bioengineered gene constructs. ASC618 has the potential to increase durability of clotting factor biosynthesis and secretion by minimizing cellular stress and induction of the unfolded protein response, which may lead to diminished FVIII production from liver cells. ASC Therapeutics will conduct a phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of ASC618. The program received IND clearance from the U.S. Food and Drug Administration. The Hemophilia Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia Treatment. Hemophilia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Hemophilia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia market. Get a detailed analysis of the latest innovations in the Hemophilia Pipeline. Explore DelveInsight's expert-driven report today! @ Hemophilia Unmet Needs Hemophilia Companies Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others. Hemophilia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intra-articular Intraocular Intrathecal Intravenous Ophthalmic Oral Parenteral Subcutaneous Topical Transdermal Products have been categorized under various Molecule types such as Oligonucleotide Peptide Small molecule Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key Hemophilia Developments @ Hemophilia Market Drivers and Barriers, and Future Perspectives Scope of the Hemophilia Pipeline Report Coverage- Global Hemophilia Companies- Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others. Hemophilia Pipeline Therapies- NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601 for Injection, Fitusiran, Marstacimab, Fitusiran, BPA prophylaxis, Concizumab, PF-06741086 and others. Hemophilia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Hemophilia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Hemophilia drug development? Find out in DelveInsight's exclusive Pipeline Report—access it now! @ Hemophilia Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Hemophilia: Overview Pipeline Therapeutics Therapeutic Assessment Hemophilia– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Fitusiran: Alnylam Pharmaceuticals Mid Stage Products (Phase II) SerpinPC: Centessa Pharmaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) Drug name: Company Name Preclinical and Discovery Stage Products Drug name: Company Name Inactive Products Hemophilia Key Companies Hemophilia Key Products Hemophilia- Unmet Needs Hemophilia- Market Drivers and Barriers Hemophilia- Future Perspectives and Conclusion Hemophilia Analyst Views Hemophilia Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

MindMed Reports Q2 2025 Financial Results and Business Updates
MindMed Reports Q2 2025 Financial Results and Business Updates

National Post

time2 hours ago

  • National Post

MindMed Reports Q2 2025 Financial Results and Business Updates

Article content –Strong enrollment continues in all three Phase 3 trials of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD)– Article content –Data from the Phase 3 Voyage trial in GAD anticipated in 1H 2026 and data from the Phase 3 Panorama trial in GAD and Phase 3 Emerge trial in MDD anticipated in 2H 2026– Article content Article content –Strengthened leadership team with appointment of Brandi L. Roberts as Chief Financial Officer– Article content –Conference call scheduled today at 4:30 p.m. EDT– Article content NEW YORK — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the 'Company' or 'MindMed'), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its second quarter 2025 financial results and provided an update on business highlights. 'We continue making significant progress across all three of our pivotal Phase 3 trials evaluating MM120 ODT in GAD and MDD, with ongoing enthusiasm from both trial sites and participants driving strong enrollment,' said Rob Barrow, Chief Executive Officer of MindMed. 'We remain on track to report topline data from our Phase 3 Voyage trial in the first half of 2026, followed by Panorama and Emerge in the second half of the year. In parallel, we are advancing our commercial strategy and have continued to strengthen our leadership team with the appointment of Brandi Roberts as Chief Financial Officer. With our clearly defined regulatory strategy, disciplined operational execution, and strong balance sheet, we are well-positioned to advance MM120 ODT as a potential best-in-class therapeutic option for the treatment of GAD and MDD.' Article content Business Highlights Article content Progressing Pivotal Trials: Strong enrollment continues across all three MM120 ODT Phase 3 trials: Voyage and Panorama in GAD and Emerge in MDD. The continued execution reinforces the Company's targeted trial timelines and progress in preparing for a potential NDA filing. Strengthened Leadership for Growth: Appointed Brandi L. Roberts as Chief Financial Officer. Ms. Roberts brings more than 25 years of financial leadership experience within the life sciences industry. As a member of the executive team, she leads all aspects of the Company's financial strategy, capital planning, accounting, investor relations and information technology. Article content MM120 ODT (lysergide D-tartrate) for GAD Article content Enrollment is on track in the Phase 3 Voyage study of MM120 ODT for the treatment of GAD. Voyage is expected to enroll approximately 200 participants in the U.S. who will be randomized 1:1 to receive MM120 ODT 100 µg or placebo. Topline data from the 12-week double-blind period (Part A) is anticipated in the first half of 2026. Enrollment is on track in the Panorama study, the Company's second Phase 3 study of MM120 ODT for the treatment of GAD. Panorama is expected to enroll approximately 250 participants (randomized 2:1:2 to receive MM120 ODT 100 µg, MM120 ODT 50 µg or placebo) in the U.S. and Europe. Topline data from the 12-week double-blind period (Part A) is anticipated in the second half of 2026. Article content MM120 (lysergide D-tartrate) for MDD Article content Enrollment is on track in the Phase 3 Emerge study of M120 ODT for the treatment of MDD. Emerge is expected to enroll 140 participants (randomized 1:1 to receive MM120 ODT 100 µg or placebo). Topline data from the 12-week double-blinded period (Part A) is anticipated in the second half of 2026. The Company expects to conduct a second Phase 3 registrational study in MDD, with the study design and timing to be informed by the progress of Emerge and additional regulatory discussions. Article content MM402 (R(-)-MDMA) for Autism Spectrum Disorder (ASD) Article content Completed a Phase 1 study of MM402, a single-ascending dose study in adult healthy volunteers. The study characterized the tolerability, pharmacokinetics and pharmacodynamics of MM402. The Company expects to initiate further studies of MM402 to assess its potential efficacy for the treatment of ASD. Article content Cash Balance. Article content As of June 30, 2025, MindMed had cash, cash equivalents and investments totaling $237.9 million compared to $245.5 million as of March 31, 2025. Article content Based on the Company's current operating plan and anticipated R&D milestones, the Company believes that its cash, cash equivalents and investments as of June 30, 2025 will be sufficient to fund the Company's operations into 2027 and at least 12 months beyond its first Phase 3 topline data readout for MM120 ODT in GAD. Article content Research and Development (R&D). Article content R&D expenses were $29.8 million for the quarter ended June 30, 2025, compared to $14.6 million for the quarter ended June 30, 2024, an increase of $15.2 million. The net increase of $15.2 million was primarily related to increases of $14.5 million related to our MM120 ODT program, $1.5 million in internal personnel costs as a result of increased headcount, and $0.2 million related to preclinical activities, offset by a decrease of $1.0 million in MM402 program expenses based on the timing of studies. Article content General and Administrative (G&A). Article content G&A expenses were $11.1 million for the quarter ended June 30, 2025, compared to $9.8 million for the quarter ended June 30, 2024, an increase of $1.3 million. The increase was primarily related to increases in personnel costs as a result of increased headcount. Article content Net Loss. Article content Net loss for the quarter ended June 30, 2025, was $42.7 million, compared to $5.9 million for the same period in 2024, a decrease of $36.8 million. The decrease was primarily due to increases in operating expenses of $16.4 million, changes in the fair value of warrants issued in our September 2022 underwritten offering of $15.6 million, the absence of a $2.5 million gain on extinguishment of contribution payable from 2024 and increased interest expense related primarily to the amendment of our credit facility of $1.8 million. Article content Conference Call and Webcast Reminder Article content MindMed management will host a webcast at 4:30 p.m. EDT today to provide a corporate update and review the Company's second quarter 2025 financial results, and business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time. Article content About MM120 Orally Disintegrating Tablet (ODT) Article content MM120 ODT (lysergide D-tartrate or LSD) is a synthetic ergotamine belonging to the group of classic, or serotonergic, psychedelics which acts as a partial agonist at human serotonin-2A (5-HT2A) receptors. MM120 ODT is MindMed's proprietary and pharmaceutically optimized form of LSD. MM120 ODT is an advanced formulation incorporating Catalent's Zydis® ODT fast-dissolve technology which has a unique clinical profile with more rapid absorption, improved bioavailability and reduced gastrointestinal side effects. MindMed is developing MM120, the tartrate salt form of lysergide, for generalized anxiety disorder (GAD), major depressive disorder (MDD), and is exploring its potential applications in other serious brain health disorders. Article content About MM402 Article content MM402 is the Company's proprietary form of R(-)-MDMA (rectus-3,4-methylenedioxymethamphetamine), being developed for the treatment of core symptoms of Autism Spectrum Disorder (ASD). MDMA is a synthetic molecule that is often referred to as an empathogen because it is reported to increase feelings of connectedness and compassion. Preclinical studies of R(-)-MDMA demonstrate its acute pro-social and empathogenic effects, while its diminished dopaminergic activity suggest that it has the potential to exhibit less stimulant activity, neurotoxicity, hyperthermia and abuse liability compared to racemic MDMA or the S(+)-enantiomer. Article content About MindMed Article content MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD. Article content Forward-Looking Statements Article content Certain statements in this news release related to the Company constitute 'forward-looking information' within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'will', 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe', 'potential' or 'continue', or the negative thereof or similar variations. Forward-looking information in this news release includes, but is not limited to, statements regarding the Company's anticipated topline readout (Part A results) for the Phase 3 Voyage study of MM120 ODT in GAD in the first half of 2026; the Company's anticipated topline readout (Part A results) for the Phase 3 Panorama study for MM120 ODT in GAD in the second half of 2026; the Company's anticipated topline readout (Part A results) for the Phase 3 Emerge study for MM120 ODT in MDD in the second half of 2026; the Company's plans to conduct a second Phase 3 study in MDD; the Company's expectations regarding the enrollment for each of the Voyage, Panorama and Emerge studies; the Company's beliefs regarding potential benefits of its product candidates; the Company's expectation to conduct further studies of MM402; the Company's expectation that its cash, cash equivalents and investments will fund operations into 2027; the Company's expectation that its cash runway will extend at least 12 months beyond its first Phase 3 topline data readout for MM120 ODT in GAD; and potential additional indications for MM120 ODT and MM402. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; compliance with laws and regulations; legislative and regulatory developments, including decisions by the Drug Enforcement Administration and states to reschedule any of our product candidates, if approved, containing Schedule I controlled substances, before they may be legally marketed in the U.S.; difficulty associated with research and development; risks associated with clinical studies or studies; heightened regulatory scrutiny; early stage product development; clinical study risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; ability to maintain effective patent rights and other intellectual property protection; as well as those risk factors discussed or referred to herein and the risks, uncertainties and other factors described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 under headings such as 'Special Note Regarding Forward-Looking Statements,' and 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and other filings and furnishings made by the Company with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, changes in expectations or otherwise. Article content Mind Medicine (MindMed) Inc. Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in thousands, except share and per share amounts) 2025 2024 2025 2024 Operating expenses: Research and development $ 29,809 $ 14,645 $ 53,166 $ 26,350 General and administrative 11,094 9,813 19,896 20,312 Total operating expenses 40,903 24,458 73,062 46,662 Loss from operations (40,903 ) (24,458 ) (73,062 ) (46,662 ) Other income/(expense): Interest income 2,774 3,116 5,207 4,772 Interest expense (2,338 ) (466 ) (2,940 ) (900 ) Foreign exchange loss, net (49 ) (32 ) (68 ) (557 ) Change in fair value of 2022 USD Financing Warrants (2,228 ) 13,445 4,771 (19,448 ) Gain on extinguishment of contribution payable — 2,541 — 2,541 Total other income/(expense) (1,841 ) 18,604 6,970 (13,592 ) Net loss (42,744 ) (5,854 ) (66,092 ) (60,254 ) Other comprehensive loss Unrealized gain on investments 36 — 46 — Gain/(loss) on foreign currency translation (31 ) (3 ) (58 ) 490 Comprehensive loss $ (42,739 ) $ (5,857 ) $ (66,104 ) $ (59,764 ) Net loss per common share, basic $ (0.50 ) $ (0.08 ) $ (0.78 ) $ (1.01 ) Net loss per common share, diluted $ (0.50 ) $ (0.26 ) $ (0.81 ) $ (1.01 ) Article content Article content Article content Article content Article content Contacts Article content For Media: Article content Article content Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store